American heart journal plus : cardiology research and practice最新文献

{"title":"Real-world effectiveness of early revascularization in stable coronary artery disease with moderate or severe ischemia","authors":"Ferdinand Jr Gerodias ,&nbsp;Robert M. Iwanochko ,&nbsp;Peter C. Austin ,&nbsp;Xuesong Wang ,&nbsp;Vladimír Džavík ,&nbsp;Shaun G. Goodman ,&nbsp;Jacob A. Udell ,&nbsp;Maral Ouzounian ,&nbsp;Heather J. Ross ,&nbsp;Lucas C. Godoy ,&nbsp;Hani Amad ,&nbsp;Mansoor Husain ,&nbsp;Douglas S. Lee","doi":"10.1016/j.ahjo.2025.100596","DOIUrl":"10.1016/j.ahjo.2025.100596","url":null,"abstract":"<div><h3>Background</h3><div>Comparative effectiveness studies may provide insights into generalizability of the ISCHEMIA trial to real-world patients. We evaluated the long-term effectiveness of revascularization within 90 days after detecting moderate or severe ischemia on myocardial perfusion imaging (MPI) in stable coronary artery disease.</div></div><div><h3>Methods</h3><div>All consecutive patients with moderate or severe ischemia (summed difference score ≥7) on single photon emission computed tomography MPI at a tertiary academic medical center were included (January 2003 to March 2020). Early revascularization (defined as percutaneous coronary intervention or coronary artery bypass grafting within 90 days) after MPI, was compared to those patients treated without early revascularization, excluding those with left main disease, severe chronic kidney disease, severe left ventricular dysfunction, recent acute coronary syndrome or heart failure hospitalization. Primary outcomes were cardiovascular death or the composite of cardiovascular hospitalization or cardiovascular death, and were tracked throughout the provincial healthcare system.</div></div><div><h3>Results</h3><div>1530 patients (mean age: 65 years; 70 % male) were followed for a median of 9.9 years. After inverse-probability treatment weighting, early revascularization was associated with lower risks of cardiovascular death (3.76 % vs 8.93 %; HR 0.54, 95 % CI: 0.31–0.91, <em>p</em> = 0.022) and a reduction in the composite endpoint (33.73 % vs 43.94 %; HR 0.67, 95 % CI: 0.49–0.92, <em>p</em> = 0.013) compared to those treated without early revascularization.</div></div><div><h3>Conclusions</h3><div>Patients with stable coronary artery disease treated with early revascularization after MPI showing moderate or severe ischemia experienced lower risks of cardiovascular death and composite of cardiovascular hospitalization or cardiovascular death compared to those treated without early revascularization.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"58 ","pages":"Article 100596"},"PeriodicalIF":1.8,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144926320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actionable arrhythmias in low-risk patients with ST segment elevation myocardial infarction (STEMI): role for continued telemetry beyond 24–48 h","authors":"Thomas Lowe ,&nbsp;Rama Mangipudi ,&nbsp;Minyoung Kim ,&nbsp;Daniel Baik ,&nbsp;Haissam Haddad ,&nbsp;Jay Shavadia","doi":"10.1016/j.ahjo.2025.100597","DOIUrl":"10.1016/j.ahjo.2025.100597","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"58 ","pages":"Article 100597"},"PeriodicalIF":1.8,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144896097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke prevention in atrial fibrillation: Why oral anticoagulation remains the standard over devices","authors":"Mohammed Ruzieh ,&nbsp;Tianze Jiao ,&nbsp;John Mandrola ,&nbsp;Andrew J. Foy","doi":"10.1016/j.ahjo.2025.100594","DOIUrl":"10.1016/j.ahjo.2025.100594","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"58 ","pages":"Article 100594"},"PeriodicalIF":1.8,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating tissue plasminogen activator (tPA) in dialysis catheter dysfunction: A focus on fibrin sheath and risk factors","authors":"Javad Jalili ,&nbsp;Sarah Vaseghi ,&nbsp;Touraj Asvadi ,&nbsp;Mahdiyeh Baastani Khajeh","doi":"10.1016/j.ahjo.2025.100595","DOIUrl":"10.1016/j.ahjo.2025.100595","url":null,"abstract":"<div><h3>Background</h3><div>Hemodialysis catheter dysfunction can arise from fibrin sheath formation, leading to impaired patency and compromised treatment. Tissue plasminogen activator (tPA) is an emerging treatment option to restore catheter patency. This study evaluated the efficacy of tPA therapy and explored clinical and demographic risk factors for catheter dysfunction.</div></div><div><h3>Methods</h3><div>This retrospective study included 42 hemodialysis patients with central venous catheters (CVCs) at <em>Imam</em> Reza Hospital, Tabriz, Iran (2020−2023). Inclusion criteria were inability to withdraw blood or inadequate flow in one or both catheter lumens, confirmed by venographic evidence of fibrin sheath formation. Patients received 2 mg tPA in 2 ml saline with a 30-min dwell time. Data on patient demographics, catheter history, and tPA outcomes were analyzed.</div></div><div><h3>Results</h3><div>tPA was effective in 78.6 % of patients after the first dose, restoring both lumens' functionality. Four of the treated cases required a second tPA session due to recurrent fibrin sheath formation within 6–18 months, all of which were successful. Two patients received a third tPA dose 14–16 months after the second, also with complete resolution. Older age (<em>p</em> = 0.02), diabetes (<em>p</em> = 0.001), and smoking (<em>P</em> = 0.015) were identified as significant risk factors for catheter dysfunction.</div></div><div><h3>Conclusion</h3><div>tPA therapy effectively restores catheter function in cases of fibrin sheath-related dysfunction. Addressing modifiable risk factors such as smoking and managing diabetes may help reduce the incidence of catheter dysfunction and improve long-term outcomes in dialysis patients.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"58 ","pages":"Article 100595"},"PeriodicalIF":1.8,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144861288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor regarding “Clinical benefit and cost effectiveness of adding life-time low-dose colchicine as secondary prevention following coronary artery bypass grafting surgery”","authors":"Parth Aphale ,&nbsp;Himanshu Shekhar ,&nbsp;Shashank Dokania","doi":"10.1016/j.ahjo.2025.100591","DOIUrl":"10.1016/j.ahjo.2025.100591","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"58 ","pages":"Article 100591"},"PeriodicalIF":1.8,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144861289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stent-assisted coil embolization for closure of coronary artery-to-pulmonary fistula with two giant beaded aneurysms: A rare case report and literature review","authors":"Jianglan Li ,&nbsp;Zhuo Chen ,&nbsp;Liping Xie ,&nbsp;Xiaorong Xiao ,&nbsp;Yanlin Luo","doi":"10.1016/j.ahjo.2025.100590","DOIUrl":"10.1016/j.ahjo.2025.100590","url":null,"abstract":"<div><h3>Background</h3><div>Coronary artery-to-pulmonary artery fistula (CPAF) complicated by giant coronary aneurysms is an exceedingly rare anomaly, with limited clinical experience.</div></div><div><h3>Case summary</h3><div>A 77-year-old woman with CPAF and giant aneurysms was diagnosed via multimodal imaging and effectively treated with stent-assisted coil embolization, underscoring its value in high-risk patients.</div></div><div><h3>Conclusion</h3><div>A comprehensive review outlines the key aspects of CPAFs with aneurysms and underscores the importance of tailored management. Although rare, CPAF with giant aneurysms poses a significant risk of rupture or ischemia. Timely diagnosis and tailored interventional management can lead to favorable outcomes.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"58 ","pages":"Article 100590"},"PeriodicalIF":1.8,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144893840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic surgical left atrial appendage occlusion: More questions than answers!","authors":"Jianguo Xu ,&nbsp;Richard P. Whitlock ,&nbsp;Emilie P. Belley-Cote","doi":"10.1016/j.ahjo.2025.100589","DOIUrl":"10.1016/j.ahjo.2025.100589","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"58 ","pages":"Article 100589"},"PeriodicalIF":1.8,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144831210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring AI use policies in manuscript writing in cardiology and vascular journals","authors":"Mustafa Alkhawam ,&nbsp;Amr Almobayed ,&nbsp;Akash Pandey ,&nbsp;Navin C. Nanda ,&nbsp;Ali J. Ebrahimi ,&nbsp;Mustafa I. Ahmed","doi":"10.1016/j.ahjo.2025.100586","DOIUrl":"10.1016/j.ahjo.2025.100586","url":null,"abstract":"<div><h3>Background</h3><div>Artificial intelligence (AI) technologies are rapidly evolving and offer efficiencies in manuscript generation however, this technology has raised concerns about the potential for bias, errors, and plagiarism to occur. In response, some journals have updated their author guidelines to address AI use.</div></div><div><h3>Methods</h3><div>We assessed author guidelines for 213 MEDLINE-indexed cardiovascular journals to evaluate policies on AI use in manuscript writing. Journal metrics such as CiteScore, Journal Impact Factor (JIF), Journal Citation Indicator (JCI), Source Normalized Impact per Paper (SNIP), and SCImago Journal Rank (SJR) were compared between journals with and without AI policies. We further analyzed the association between AI policy adoption and society affiliation. We reviewed the criteria for listing AI as an author and allowances for AI-generated content.</div></div><div><h3>Results</h3><div>Of 213 journals, 170 (79.8 %) had AI policies consistent across evaluations. Policies were present in 115 of 147 (78 %) cardiology journals and 113 of 127 (89 %) vascular journals. Furthermore, 111 of 143 (77.6 %) had AI-use policies, while 59 out of 70 (84.2 %) were unaffiliated journals. Journal metrics did not significantly differ between journals with and without AI policies (<em>P</em> &gt; 0.05). Among journals with policies, 156 out of 158 (98.7 %) excluded AI as authors, while all allowed AI-assisted content.</div></div><div><h3>Conclusion</h3><div>Many cardiovascular journals address AI-generated content, but gaps remain in policies and disclosure requirements for AI-created manuscripts. The presence of AI-use policies was independent of journal metrics or society affiliation.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"58 ","pages":"Article 100586"},"PeriodicalIF":1.8,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144841403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigating atherosclerosis: Integrating vaccines with gene targets.","authors":"Alireza Haraj, Masoomeh Bakhshandeh, Nafiseh Shokri, Prand Shariat Rad, Ali Alyan, Zahra Chegini, Mohammad Ali Nazari, Seyed Parsa Seyedi Taji, Mohammad Najafi","doi":"10.1016/j.ahjo.2025.100588","DOIUrl":"10.1016/j.ahjo.2025.100588","url":null,"abstract":"<p><p>The formation and progression of atherosclerotic plaques occur through cellular dysfunction and remodeling of the extracellular matrix in the sub-endothelial space of vessels. The immunity against specific antigens is suggested to mitigate the atherosclerosis process. Primarily, studies have suggested that certain antigens, such as ox-LDL, ApoB-100, CETP, PCSK9, HSP60, MHC-II-derived peptides, and interleukins, are involved in atherosclerosis. However, recognizing the intricate interplay between immune responses and the formation of arterial plaques is essential to optimize immunization against atherosclerosis. In this review, the roles of some genes were presented in triggering atherosclerotic plaque events. Furthermore, some immunization approaches are presented to target these genes. The studies suggested that vaccination against the progression of atherosclerosis is an essential and effective approach to reducing the high death rate in autoimmune diseases.</p>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"57 ","pages":"100588"},"PeriodicalIF":1.8,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12351348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144876924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum uric acid, renal status, cardiovascular-kidney-metabolic syndrome and drug therapy, a wide-angled Mendelian randomization analysis","authors":"Lingyun Luo ,&nbsp;Xuelian Luo ,&nbsp;Zhen He","doi":"10.1016/j.ahjo.2025.100587","DOIUrl":"10.1016/j.ahjo.2025.100587","url":null,"abstract":"<div><h3>Background</h3><div>Serum uric acid (SUA) and renal status are associated with the Cardiovascular-Kidney-Metabolic (CKM) syndrome. However, the causal association among them along with drug therapy need to be explored.</div></div><div><h3>Methods</h3><div>We employed univariable, multivariate, mediation and drug-target mendelian randomization. Inverse variance weighting was the primary result, with extensive sensitivity analyses conducted to ensure robustness and reliability.</div></div><div><h3>Results</h3><div>Regarding SUA, genetically predicted SUA demonstrated a potential risk effect on stage 4 of CKM syndrome (ischemic heart disease (IHD), OR = 1.090, 95 %CI: 1.003–1.184; peripheral artery disease, OR = 1.174, 95 %CI: 1.058–1.303). SUA remained a significant risk factor after excluding the confounding of eGFR and proteinuria (IHD: OR = 1.137, 95 %CI: 1.043–1.238; peripheral artery disease: OR = 1.224, 95 %CI: 1.107–1.354). SUA mediated the following causal effect: sleep apnea (2.37 %), income (1.92 %) and education (1.79 %) on IHD; C-reactive protein (11.65 %) and education (4.29 %) on peripheral artery disease. Regarding renal status, renal dysfunction led to a wider phenotype of CKM syndrome including hypertension, cerebrovascular disease, chronic kidney disease and renal failure. Similarly, renal status mediated the causal effect of education on hypertension (1.84 %), depression on cerebrovascular (0.46 %) and family history of diabetes on chronic kidney disease (3.49 %) and renal failure (2.81 %). Lesinurad targeting SLC22A11 and SLC22A12 was validated for treating IHD.</div></div><div><h3>Conclusion</h3><div>Our study clarified the complex relationship among SUA, renal status and CKM syndrome. Simultaneously providing innovative drug and social interventions for CKM syndrome.</div></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"57 ","pages":"Article 100587"},"PeriodicalIF":1.8,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}